Day: April 19, 2024

VANCOUVER, British Columbia, April 19, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that, further to its press release dated April 10, 2024 (the “April 10 Release”), the Company has closed its previously announced non-brokered private placement offering (the “Offering”) effective today (the “Closing Date”) through the issuance of 4,166,665 Units for gross proceed of $750,000. Capitalized terms not otherwise defined herein have the meanings attributed to them in the April 10 Release. Each Unit was sold at a price of $0.18 per Unit and consisted of one Common Share and one-half of one Warrant....

LOS ANGELES, April 19, 2024 (GLOBE NEWSWIRE) — NASDAQ-listed, AGBA Group Holding Limited (“AGBA”), has previously announced that on April 16, 2024, it had entered into a definitive merger agreement (the “Merger Agreement”) to combine AGBA with Triller Corp. (“Triller”), a leading Artificial Intelligence-driven social video platform (together, the “Merger” or the “Transaction”). Upon completion of the Transaction, AGBA will become a Delaware corporation that wholly owns Triller, and AGBA itself will be majority-owned (80%) by current Triller stockholders and restricted stock unit (“RSU”) holders.The Boards of Directors of Triller and AGBA have agreed to value the Combined Group (i.e. AGBA + Triller) at US$4.0 billion. Triller shareholders (including holders of Triller RSUs) will own 80% of the pro forma Combined Group representing...

Company Announcement no. 03-2024 Copenhagen, 19th April 2024 The annual general meeting of Swiss Properties Invest A/S was held today in accordance with the agenda in the notice of 5th April 2023 convening the annual general meeting, cf. company announcement No 02-2024 of 5th April 2024. At the annual general meeting the following resolutions were agreed upon:The approval of the annual accounts and consolidated annual accounts, with audit report and annual report. The appropriation of profits according to the approved annual accounts. The discharge to the board of directors for 2023. The approval of the remuneration to the board of directors for the current financial year. The re-election of Thorbjørn Graarud, Christian Seidelin, Kirsten Sillehoved to the board of directors. The re-election of BDO Statsautoriseret Revisionsaktienselskab...

NEW YORK, April 19, 2024 (GLOBE NEWSWIRE) — Collective Audience, Inc. (Nasdaq: CAUD), a leading innovator of audience-based performance advertising and media, has appointed Stacey Hawes to the Advisor Collective, the strategic advisory board the company formed earlier this year to support the transformation and advancement of the AdTech, MarTech and digital media industries.Hawes is an award-winning AdTech/MarTech executive with more than 25 years of success helping hundreds of brands to leverage the power of data-driven marketing and drive exponential growth. “Stacey’s extraordinary experience and history of achievement greatly enriches our Advisor Collective,” commented Collective Audience CEO, Peter Bordes. “As a contributing member of this growing collective of innovators and thought leaders, we see Stacey playing an important...

The Annual General Meeting, led by Chairman of the Board Dan Frohm, decided to:adopt the income statement and balance sheet as well as the consolidated income statement and consolidated balance sheet, discharge the members of the Board and the Chief Executive Officer from liability for the financial year 2023, according to the proposal in the summons, distribute a dividend of SEK 4.15 per share for 2023. The record date for the dividend is proposed to be 23 April 2024 and it is expected that the dividend will be disbursed by Euroclear Sweden AB on 26 April 2024, for the financial year 2024 grant, according to the proposal in the summons, the Board a remuneration of a total of SEK 4,512,600 including reimbursement for committee work, to be divided among the members as presented in the summons, appoint, according to the proposal in the...

NEW YORK, April 19, 2024 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company’s website for at least 30 days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with...

NEW YORK, April 19, 2024 (GLOBE NEWSWIRE) — Perella Weinberg Partners (“PWP”) (NASDAQ:PWP), a leading global independent advisory firm, today announced that it plans to release its financial results for the first quarter 2024 on Friday, May 3, 2024, before the market opens. Conference Call and WebcastManagement will host a conference call and webcast to review PWP’s results on the same day at 9:00AM ET. A webcast of the conference call will be available to the public on a listen-only basis and can be accessed through the Investors section of PWP’s website at https://investors.pwpartners.com. The conference call can also be accessed by the following dial-in information:Domestic: (800) 343-4136 International: (203) 518-9848 Conference ID: PWPQ124ReplayA replay of the call will also be available two hours after the live...

Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar to Humira® The agreement broadens patient access and further commitment to availability of vital biologics in the U.S. and globallyAlvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryvk in the U.S. market, the newly U.S. Food and Drug Administration (FDA) approved high-concentration interchangeable biosimilar to Humira. “This new partnership agreement supports our financial guidance and reflects Alvotech’s strong commitment to increasing patient...